Evidence map›Paper›PMID 40821395›Full record

ArticleClinical and translational radiation oncology2025

Reirradiation of recurrent glioblastoma: Results from a single-center retrospective cohort study.

Cas S Dejonckheere, Thomas Zeyen, Cathrina Duffy, Yannik C Layer, Anna-Laura Potthoff, Barbara D Wichtmann, Lea L Friker, Davide Scafa, Christina Leitzen, Younèss Nour and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Cas S DejonckheereDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Thomas ZeyenDepartment of Neurooncology, Center for Neurology and Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
Cathrina DuffyDepartment of Neurooncology, Center for Neurology and Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
Yannik C LayerDepartment of Radiology, University Hospital Bonn, Bonn, Germany.
Anna-Laura PotthoffDepartment of Neurosurgery, University Hospital Bonn, Bonn, Germany.
Barbara D WichtmannDepartment of Neuroradiology, University Hospital Bonn, Bonn, Germany.
Lea L FrikerInstitute of Neuropathology, University Hospital Bonn, Bonn, Germany.
Davide ScafaDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Christina LeitzenDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Younèss NourDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Fabian KugelDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Niklas SchäferDepartment of Neurooncology, Center for Neurology and Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
Alexander RadbruchDepartment of Neuroradiology, University Hospital Bonn, Bonn, Germany.
Hartmut VatterDepartment of Neurosurgery, University Hospital Bonn, Bonn, Germany.
Anca-Ligia GrosuDepartment of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Ulrich HerrlingerDepartment of Neurooncology, Center for Neurology and Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
Matthias SchneiderDepartment of Neurosurgery, University Hospital Bonn, Bonn, Germany.
Frank A GiordanoDepartment of Radiation Oncology, University Medical Center Mannheim, Mannheim, Germany.
Gustavo R SarriaDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Eleni GkikaDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Julian P LayerDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The management of recurrent glioblastoma (rGBM) remains a clinical challenge, with only limited therapeutic options available to date. Reirradiation may offer a progression-free survival (PFS) benefit in selected cases, but data are scarce. Methods: Consecutive patients from the last 10 years with GBM (CNS WHO grade 4, IDH-wildtype) who underwent at least one additional course of cranial radiotherapy for suspected or histopathologically confirmed rGBM at a tertiary neuro-oncological center were retrospectively analyzed. The primary endpoint was PFS, secondary endpoints included reirradiation-related adverse event rates, with a particular focus on radiation necrosis (RN). Results: Fifty-nine patients were included with a median follow-up (range) of 8.7 (0.5-48.0) months after reirradiation. The median time to first recurrence was 15 (4-89) months, with the majority occurring in-field (59.7 %). The EQD2 Conclusion: In this retrospective analysis, reirradiation for rGBM was feasible and safe, conferring a potential PFS benefit in selected patients. Bevacizumab emerged as a particularly promising combination partner, contributing to both RN prevention and enhanced efficacy.

Indexed as

GlioblastomaRadiation necrosisRecurrenceReirradiation

Identifiers

PMID40821395
PMCPMC12357250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.